Autoantibody profiling and anti-kinesin reactivity in ANCA-associated vasculitis

Dataset from Federica Mescia, Shaghayegh Bayati, Elisabeth Brouwer, et al. Autoantibody profiling and anti-kinesin reactivity in ANCA-associated vasculitis. Int J Mol Sci. Accepted on 17 October 2023. https://www.mdpi.com/1422-0067/24/20/15341

Abstract:

ANCA-associated vasculitides (AAV) are rare autoimmune diseases causing inflammation and damage of small blood vessels. New autoantibody biomarkers are needed to improve the diagnosis and treatment of AAV patients. In this study, we aimed to profile the autoantibody repertoire of AAV patients using in-house developed antigen arrays to identify previously unreported antibodies linked to the disease per se, clinical subgroups, or clinical activity. A total of 1743 protein fragments representing 1561 unique proteins were screened in 229 serum samples collected from 137 AAV patients at presentation, remission, and relapse. Additionally, serum samples from healthy individuals and patients with other type of vasculitis and autoimmune-inflammatory conditions were included to evaluate the specificity of the autoantibodies identified in AAV. Autoreactivity against members of the kinesin protein family were identified in AAV patients, healthy volunteers and disease controls. Anti-KIF4A antibodies were significantly more prevalent in AAV. We also observed possible associations between anti-kinesin antibodies and clinically relevant features within AAV patients. Further verification studies will be needed to confirm these findings.

This dataset contains relative continuous as well as binarized autoantibody data, with associated diagnosis (e.g. ANCA-vasculitis - GPA or MPA, giant cell arteritis, polymialgia rheumatica, healthy individuals), serological data (anti-MPO and anti-PR3), treatment and evaluation of the disease status (active or non-active). Longitudinal measurements are available for ANCA-vasculitis.

Data Access Statement

These data constitute sensitive personal information that fall under the GDPR. Therefore, access to data and related code is restricted. The data can be made available for validation purposes, upon reasonable request and in accordance with GDPR.

A reasonable request should contain:
1) Name of PI and host organisation
2) Contact details
3) Scientific purpose of data access request
4) Commitment to inform when the data has been used in a publication
5) Commitment not to host or share the data outside the requesting organisation
6) Statement of non-commercial use of data